Haemonetics

HAE

Market cap $2.94B

BOSTON, Feb. 23, 2026 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative solutions designed to improve patient outcomes, today announced U.S. Food and Drug Administration (FDA) 510(k) clearance for the NexSys PCS ®  Plasma Collection System with Persona ®  PLUS technology. Persona PLUS represents the next generation of Haemonetics' proprietary and patented Persona technology that tailors plasma collections to each donor for improved average plasma volume per donation.

BOSTON, Feb. 20, 2026 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that Chris Simon, President and CEO, will participate in a fireside chat with investors at the Raymond James 47th Annual Institutional Investors Conference on Monday, March 2, 2026 at 10:25 a.m. ET. The public may access a live webcast of the fireside chat at Haemonetics' Investor Relations website or at the following link: https://event.summitcast.com/view/VSr8zRPFYu9jT7Rm69ptdC/DrZt2UmuNYtnB5faJBzE4N.

The London Company Small Cap portfolio increased 2.7% (2.5% net) during the quarter vs. a 2.2% increase in the Russell 2000 Index. Contributors to relative performance were White Mountains Insurance Group Ltd, Revolve Group Inc. and Haemonetics Corporation. Detractors from relative performance were NewMarket Corporation, Certara, Inc. and Gates Industrial Corporation plc.

Evaluate Haemonetics' (HAE) reliance on international revenue to better understand the company's financial stability, growth prospects and potential stock price performance.

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Haemonetics Corporation (NYSE: HAE) reported upbeat earnings for its third quarter on Thursday.

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

HAE beats Q3 EPS and revenue estimates as margins expand sharply, but sales fall 2.7% year over year, sending shares down after the report.

Haemonetics Corporation (HAE) Q3 2026 Earnings Call Transcript

While the top- and bottom-line numbers for Haemonetics (HAE) give a sense of how the business performed in the quarter ended December 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.